Sestrin2 inhibits RANKL-induced osteoclastogenesis through AMPK activation and ROS inhibition
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
Sestrins are stress-responsive proteins with antioxidant properties. They participate in cellular redox balance and protect against oxidative damage. This study investigated the effects of Sestrin2 (Sesn2) on osteoclast differentiation and function. Overexpressing Sesn2 in osteoclast precursor cells significantly inhibited receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclastogenesis. This was assessed as reduced expression of various osteoclast markers, including c-Fos, nuclear factor of activated T cells 1 (NFATc1), osteoclast-associated receptor, tartrate-resistant acid phosphatase, and cathepsin K. Conversely, downregulation of Sesn2 produced the opposite effect. Mechanistically, Sesn2 overexpression enhanced AMPK activation and the nuclear translocation of nuclear factor erythroid-derived factor 2-related factor 2 (Nrf2), promoting antioxidant enzymes. Moreover, azithromycin (Azm) induced Sesn2 expression, which suppressed RANKL-induced osteoclast differentiation. Specifically, Azm treatment reduced RANKL-induced production of reactive oxygen species in osteoclasts. Furthermore, intraperitoneal administration of Azm ameliorated RANKL-induced bone loss by reducing osteoclast activity in mice. Taken together, our results suggested that Azm-induced Sesn2 act as a negative regulator of RANKL-induced osteoclast differentiation through the AMPK/NFATc1 signaling pathway. Concisely, targeting Sesn2 can be a potential pharmacological intervention in osteoporosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:211 |
|---|---|
| Enthalten in: |
Free radical biology & medicine - 211(2024) vom: 01. Feb., Seite 77-88 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Kabsun [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.01.2024 Date Revised 17.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.freeradbiomed.2023.12.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365922773 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365922773 | ||
| 003 | DE-627 | ||
| 005 | 20240218231916.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.freeradbiomed.2023.12.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1298.xml |
| 035 | |a (DE-627)NLM365922773 | ||
| 035 | |a (NLM)38101586 | ||
| 035 | |a (PII)S0891-5849(23)01154-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Kabsun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sestrin2 inhibits RANKL-induced osteoclastogenesis through AMPK activation and ROS inhibition |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.2024 | ||
| 500 | |a Date Revised 17.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Sestrins are stress-responsive proteins with antioxidant properties. They participate in cellular redox balance and protect against oxidative damage. This study investigated the effects of Sestrin2 (Sesn2) on osteoclast differentiation and function. Overexpressing Sesn2 in osteoclast precursor cells significantly inhibited receptor activator of nuclear factor κB ligand (RANKL)-induced osteoclastogenesis. This was assessed as reduced expression of various osteoclast markers, including c-Fos, nuclear factor of activated T cells 1 (NFATc1), osteoclast-associated receptor, tartrate-resistant acid phosphatase, and cathepsin K. Conversely, downregulation of Sesn2 produced the opposite effect. Mechanistically, Sesn2 overexpression enhanced AMPK activation and the nuclear translocation of nuclear factor erythroid-derived factor 2-related factor 2 (Nrf2), promoting antioxidant enzymes. Moreover, azithromycin (Azm) induced Sesn2 expression, which suppressed RANKL-induced osteoclast differentiation. Specifically, Azm treatment reduced RANKL-induced production of reactive oxygen species in osteoclasts. Furthermore, intraperitoneal administration of Azm ameliorated RANKL-induced bone loss by reducing osteoclast activity in mice. Taken together, our results suggested that Azm-induced Sesn2 act as a negative regulator of RANKL-induced osteoclast differentiation through the AMPK/NFATc1 signaling pathway. Concisely, targeting Sesn2 can be a potential pharmacological intervention in osteoporosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a AMP-Activated protein kinase | |
| 650 | 4 | |a Azithromycin | |
| 650 | 4 | |a Nuclear factor erythroid-derived factor 2-related factor 2 | |
| 650 | 4 | |a Osteoclast | |
| 650 | 4 | |a Reactive oxygen species | |
| 650 | 4 | |a Sestrin2 | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 650 | 7 | |a RANK Ligand |2 NLM | |
| 650 | 7 | |a AMP-Activated Protein Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.31 |2 NLM | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a NFATC Transcription Factors |2 NLM | |
| 700 | 1 | |a Kim, Jung Ha |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Inyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Seong, Semun |e verfasserin |4 aut | |
| 700 | 1 | |a Koh, Jeong-Tae |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Nacksung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Free radical biology & medicine |d 1989 |g 211(2024) vom: 01. Feb., Seite 77-88 |w (DE-627)NLM012613827 |x 1873-4596 |7 nnns |
| 773 | 1 | 8 | |g volume:211 |g year:2024 |g day:01 |g month:02 |g pages:77-88 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.freeradbiomed.2023.12.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 211 |j 2024 |b 01 |c 02 |h 77-88 | ||